Sangamo BioSciences announces evidence of HIV functional control with SB-728-T

|About: Sangamo Therapeutics, Inc. (SGMO)|By:, SA News Editor

Sangamo BioSciences (SGMO) presents what it says is "the first evidence that sustained functional control of HIV in the absence of antiretroviral therapy is possible."

The company says viral load became undetectable during an ART treatment interruption in three of seven patients treated with SB-728-T.

In one patient, viral load has been undetectable for seven weeks.

The company calls this "a major step toward immunological functional control of HIV." (PR)

SGMO +3.2% AH